Related Experiment Videos
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of
Abstract:
Matrix metalloproteinases (MMPs) are a family of endopeptidases capable of enzymatic digestion of subendothelial basement membrane and other components of the extracellular matrix. Expression of MMP-2, -3, -7 and -9 is increased around multiple sclerosis plaques and in brain tissue in experimental allergic encephalomyelitis. To measure quantitatively the expression of these MMPs and their endogenous inhibitors (TIMP-1 and -2), we analysed samples from 52 patients with relapsing-remitting and primary progressive multiple sclerosis by ELISA (enzyme-linked immunosorbent assay) and substrate-gel electrophoresis (zymography). MMP-9 was increased over controls in 100% of relapsing-remitting multiple sclerosis cases, with similar levels detected in relapses and clinically stable phases of disease. In primary progressive multiple sclerosis, MMP-9 was increased in 57% of CSF samples, but concentrations were below those encountered in the relapsing-remitting form. The selective upregulation of MMP-9 suggests that T-cells and macrophages invading the brain parenchyma and the CSF space are the predominant source of MMP-9 in multiple sclerosis. TIMPs and other MMPs (MMP-2 and -3) were not upregulated or not detectable (MMP-7) in CSF of patients with relapsing-remitting and primary progressive multiple sclerosis. The sustained increase of MMP-9 in clinically stable multiple sclerosis supports the concept that multiple sclerosis is associated with ongoing proteolysis that may result in progressive tissue damage. The selective inhibition of MMP-9 could be a useful approach for the prevention of disease progression in multiple sclerosis.
Insights
Matrix metalloproteinases (MMPs), specifically MMP-9, are elevated in multiple sclerosis (MS) patients. This sustained increase in MMP-9 suggests ongoing tissue damage and potential therapeutic targets for MS progression.
Area of Science:
- Neuroimmunology
- Biochemistry
- Enzymology
Background:
- Matrix metalloproteinases (MMPs) degrade extracellular matrix components.
- Elevated MMP expression is observed in multiple sclerosis (MS) and experimental allergic encephalomyelitis.
- MMP-2, -3, -7, and -9 are implicated in MS pathogenesis.
Purpose of the Study:
- To quantitatively assess MMP-2, -3, -7, -9, and their inhibitors (TIMP-1, -2) in MS patients.
- To correlate MMP levels with disease activity and progression in relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).
Main Methods:
- Analysis of cerebrospinal fluid (CSF) and tissue samples from 52 MS patients.
- Enzyme-linked immunosorbent assay (ELISA) for quantitative MMP and TIMP measurement.
- Substrate-gel electrophoresis (zymography) for MMP activity assessment.
Main Results:
- MMP-9 was significantly increased in 100% of RRMS cases, irrespective of disease phase.
- MMP-9 was elevated in 57% of PPMS CSF samples, but at lower concentrations than in RRMS.
- MMP-2, -3, and -7, along with TIMP-1 and -2, showed no significant upregulation in MS CSF.
Conclusions:
- Selective upregulation of MMP-9, likely from T-cells and macrophages, is a key feature of MS.
- Sustained MMP-9 increase in stable MS indicates ongoing proteolysis and potential for progressive tissue damage.
- Targeting MMP-9 may offer a therapeutic strategy to prevent MS progression.